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Abstract.
The enzyme cyclooxygenase-2 (COX-2), responsible for the
first committed step in the synthesis of several important
mediators which are involved in both initiation and
resolution of inflammation, and the subsequent generation
of prostaglandins (PGs) upon activation has been shown to
participate in the neurodegenerative processes of a variety
of diseases. This review looks particular at the role of COX-2
in the pathogenesis of Parkinson’s disease, involving the
generation of PGs and the role of the two different parts of
the cyclooxygenase—cyclooxygenase and peroxidase
activity.
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1. Introduction
Neuroinflammation has long been implicated in the pathoge-
nesis of a variety of neurodegenerative diseases, as Alzhei-
mer’s disease, amyotrophic lateral sclerosis, and Parkinson’s
disease (PD) [1]. Markers of inflammation, particularly an
increase in activated microglia, have been reported in PD
[2,3]. Furthermore, an increased expression of cyclooxygen-
ase-2 (COX-2) has long been associated with the disease.
Cyclooxygenase (COX) is the main enzyme responsible for
the conversion of arachidonic acid into prostaglandin (PG)
H2, which is the main precursor of the different PGs, but in
particular PGE2. COX comes in three different isoforms: 1)
COX-1, which is in general constitutively expressed and pres-
ent in many cell types. 2) COX-2, which in general is
expressed on a wide array of stimuli, in particular in
response to N-methyl-D-aspartate (NMDA)—dependent syn-
aptic activity [4]. Furthermore, a low level of COX-2 expres-
sion can be found in the central nervous system [5]. 3) COX-
3, made from the COX-1 gene, was first described in 2002
[6]. It has been linked to the action of acetaminophen (para-
cetamol), as the drug possesses weak COX-1 and COX-2 in-
hibitory effects, but potent antipyretic and analgesic activity.
COX-3 seems to be constitutively expressed, and is either an
enzyme of its own, derived by the COX-1 gene, or a variant
of COX-1 (or even COX-2) (for a discussion on the issue see
ref. 7). It has to be mentioned that, after the initial enthusi-
asm for the discovery, COX-3 functional role in human brain
remains, at present, uncertain [8,9].
All Cox enzymes catalyze the formation of PGs from ar-
achidonic acid. In a first cyclooxygenase reaction, arachi-
donic acid and two O2 molecules are converted to form
PGG2. In the second, peroxidase reaction step PGG2 is
reduced by two electrons to form PGH2 [10]. The main differ-
ences between COX-1 and COX-2 in peroxidase activity are
determined by two facts: first of all by the kinetics involved:
Intermediates appearing in the second step of PGH2 genera-
tion are far more rapidly formed by COX-2 than COX-1. Sec-
ond: COX-1 utilizes a two-electron reduction of hydroperoxi-
dase substrates whereas in the case of COX-2 it is to 40%
one-electron reduction [11]. The one electron reduction has
long been implicated to lead to the leakage of electrons,
which in turn could react with cellular oxygen to form reac-
tive oxygen species [12,13]. Interestingly enough, it has been
reported that only carbon-centered radicals are generated in
the COX-2/arachidonic acid system and are responsible for
the generation of oxidative stress [14].
Based on the hypothesis that peroxidase activation of
COX-2 can be detrimental the role of COX-2 peroxidase as
well as COX-2 cyclooxygenase activity has been investigated
in detail. A study using adenoviral overexpression of COX-2
with a mutation in the peroxidase site of COX-2 led to simi-
lar susceptibility to hypoxia compared with those cells over-
expressing normal COX-2 [15] In contrast, a mutation in the
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cyclooxygenase site led to a protective effect against hy-
poxia. The authors hypothesize that the protective effect is
caused by the inability of arachidonic acid to bind to the
modified COX-2 and thus the enzyme cannot generate PGs
[15,16]. Recently, a new mouse model for specific cyclooxy-
genase ablation, leaving peroxidase activity intact, has been
generated [17], modeling the specific COX-2 inhibition of
newer COX-2 inhibitors such as celecoxib and rofecoxib. The
authors report that COX-1 and COX-2 can form heterodimers,
which are capable of producing PGs. Unfortunately it seems
that current techniques will not be able to distinguish
between the effect of specific COX-2 inhibition on COX-2
homodimers or COX-1-COX-2 heterodimers [17]. Still the
model provides a new tool in dissecting the different COX-2
mechanisms to generate new substances, which in the end
might provide the beneficial effect as seen in disease mod-
els, without the sometimes severe side-effects.
2. COX-2 in models of Parkinson’s
disease
The main neurotoxin models to study PD are based on the
administration of a neurotoxin as 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP) or 6-hydroxydoamine (6-OHDA) (a
review on the models can be found in ref. 18). Inhibition of
COX-2 by acetylsalicylic acid and salicylate provided neuropro-
tection in the MPTP-model [19,20], whereas diclofenac showed
no neuroprotective effect. The later could be dependent on its
failure to penetrate the blood–brain barrier, as on the other
hand meloxicam was able to protect against MPTP-induced
toxicity [20]. Using COX-2 deficient mice, a significant role for
COX-2 in the MPTP-model was confirmed, as these mice
showed significant protection against MPTP-induced neurode-
generation [21,22]. COX-2 was mainly expressed in dopaminer-
gic neurons after MPTP, which is partially in contrast to
another publication who describes a more abundant expres-
sion of COX-2 in microglia [23]. Differences could be related to
technical differences; nevertheless, both studies agree that
neurons compose the majority of COX-2 positive cells in PD.
Interestingly enough, microglia expression was not
reduced after MPTP in COX-2 deficient mice, despite the fact
of a reduction in cellular loss. This could be due to the fact,
that a very harsh MPTP regimen was used (4  20 mg//kg
i.p. 2 h apart), and not the ‘‘sub-acute’’ or chronic model (30
mg/kg i.p. over five consecutive days) of the disease, leading
to a more progressive invasion of microglia. Besides, other
factors which contribute to the cellular demise as inducible ni-
tric oxide (iNOS) were not affected. Further investigation
showed that dopamine-quinone, a by-product generated by
COX-2 activity was highly upregulated. In turn, mice which
received the COX-2 inhibitor rofecoxib did not show any
attenuation of dopamine quinone expression after MPTP when
compared to saline-treated control animals. As described pre-
viously, COX-2 can lead to the oxidation of dopamine to form
dopamine-quinone [24], which in turn is highly reactive. Dopa-
mine-quinone can react with cysteinyl residues in proteins,
leading to protein transformation and subsequently to altera-
tion of protein function. This in turn can have led to the cell
death observed after MPTP, and thus be one explanation for
the protective effect of COX-2 ablation [21].
A second pathway by which COX-2 possibly leads to
cellular demise after MPTP is by increasing the levels of
PGE2. PGE2 levels were only slightly affected by COX-2 abla-
tion after MPTP administration in our studies, but again, this
could be due to the fact, that a ‘‘harsh’’ regimen of MPTP
administration was used. Increased turnover of PGE2 can
lead to elevated levels of reactive oxygen species [25] and,
PGE2 can lead to the activation of astrocytes [26].
Additionally, PGE2 can interact with different EP recep-
tors, thus promoting neurodegeneration (a full review of the
four different PG E receptors can be found in ref. 27). Of the
receptors described, only the EP2 receptor has been studied in
a model of PD. Microglial activation and associated neurotoxic-
ity seems to be mediated by EP2 [28], as EP2 deficient mice
showed protection against MPTP-induced toxicity. Also, EP2/
microglia enhanced the clearance of a-synuclein in tissue sec-
tions obtained from patients with Lewy body disease. On the
other hand, the EP2 receptor protects against 6-OHDA toxicity
in a cell culture model [29]. One has to keep in mind that the
later study uses cell culture, lacking microglia, and EP2 seems
to act via microglia. Thus, it is questionable if the later study
indeed describes reliably an effect which could be reproduced
in vivo. It is also described that lipopolysaccharide (LPS) does
not induce secondary neurotoxicity in conditioned medium
from EP2/ microglia, suggesting an important role for EP2 in
inflammatory reactions and LPS-mediated neurotoxicity [30].
Looking at EP1 it becomes clear that this receptor might
also contribute to PGE2-mediated toxicity. It has been
described to make neurons more susceptible to oxidative
stress in a cell culture model of PD [31]. EP1 receptors seem
to be the main pathway by which COX-2 mediates neurotoxic-
ity through disruption of Ca2þ homeostasis [32]. Another path-
way by which EP1 could mediate toxicity is by reducing energy
levels, as activation of the EP1 receptor has been shown to
lead to a long duration oxygen-glucose deprivation [33].
Additionally, the expression of pro-inflammatory cyto-
kines such as IL-6 is regulated by PGE2 in various cell-types
like macrophages and astrocytes [34–36]. Selective antibody
neutralization of PGE2 inhibits IL-6 production, hyperalgesia,
and the inflammatory process in a model of carrageen-
induced paw-inflammation [37]. Whether this pathway—COX-
2—IL-6 also plays a role in PD remains to be shown as stud-
ies investigating the role of COX-2 and IL-6 only have shown
a parallel increase [38,39].
Taken together we can say that COX-2 plays a funda-
mental part in the pathogenesis of PD, and if only as a prop-
agator of the disease. Inhibition of COX-2 remains a valuable
target as a potential neuroprotective treatment strategy
aimed at slowing or halting the progression of the disease.
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